肿瘤细胞治疗研究
英文原题：Survival analysis and prognostic factors of mature T-cell and natural killer/T-cell neoplasms in Colombian patients from 2008-2025.
这些发现凸显了T细胞淋巴瘤显著的临床异质性，并验证了ECOG和LDH在拉丁美洲的预后价值。
T细胞淋巴瘤呈现全球性差异，但拉丁美洲的研究仍然有限。主要结局 本研究旨在确定T细胞淋巴瘤的亚型分布频率、治疗和总生存期。
我们开展了一项回顾性队列研究，纳入101例成熟T/NK细胞肿瘤患者（2008-2025年）。采用Kaplan-Meier估计和Cox模型分析生存（OS和PFS）。
中位年龄为58岁。PTCL-NOS（31.7%）、间变性大细胞淋巴瘤（20.8%）和结外NK/T细胞淋巴瘤（18.8%）是最常见的亚型。36个月OS为57.8%，PFS为42.1%。观察到显著的预后异质性，其中间变性大细胞淋巴瘤预后最佳，T-幼淋巴细胞白血病预后最差。在多变量分析中，ECOG状态2独立预测更高的死亡率（HR = 2.73，p<0.001），而低LDH水平降低风险（HR：0.22；95% CI：0.08-0.61；p = 0.003）。
BACKGROUND: T-cell lymphomas show global variation, but research in Latin America remains limited. The main outcome This study aimed to determine, subtype distribution frequency, treatment, and overall survival of T-cell lymphoma. METHODS: We conducted a retrospective cohort study of 101 patients with mature T/NK-cell neoplasms (2008-2025). Survival (OS and PFS) was analyzed using Kaplan-Meier estimates and Cox models. RESULTS: Median age was 58 years. PTCL-NOS (31.7%), anaplastic large cell lymphoma (20.8%), and extranodal NK/T-cell lymphoma (18.8%) were the most frequent subtypes. The 36-month OS was 57.8% and PFS was 42.1%. Significant prognostic heterogeneity was observed, with anaplastic large cell lymphoma showing the best and T-prolymphocytic leukemia the poorest outcomes. In multivariable analysis, ECOG status 2 independently predicted higher mortality (HR = 2.73, p<0.001), while low LDH levels reduced risk (HR: 0.22; 95% CI: 0.08-0.61; p = 0.003). CONCLUSIONS: These findings highlight the marked clinical heterogeneity of T-cell lymphomas and validate the prognostic value of ECOG and LDH in Latin America.
MEMBER ACCOUNT
登录成功会直接打开下一页。
